W-DB53

W-DB53 is a selective small-molecule protein-protein interaction (PPI) inhibitor designed to disrupt the interaction between OTU domain-containing protein 4 (OTUD4) and 5'-nucleotidase (CD73). Developed by researchers at the Emory Winship Cancer Institute, the compound targets an OTUD4-driven proteolytic axis that hyperactivates CD73-mediated adenosinergic signaling in the context of obesity-associated triple-negative breast cancer (TNBC). By disrupting this axis, W-DB53 depletes lipid-laden tumor-associated macrophages (LL-TAMs), restores cytotoxic T-cell infiltration, and reprograms efferocytosis within the tumor microenvironment. Preclinical studies indicate that W-DB53 can overcome obesity-driven immune resistance and synergize with immune checkpoint inhibitors (ICIs).